Skip to main content
Displaying 25 - 36 of 275
Display:
12
24
48
General Hepatology
5
LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023
View
General Hepatology
7
Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023
View
General Hepatology
5
LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023
View
General Hepatology
5
LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024
View
Liver Tumours
6
Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024
View
Pagination
First page
« First
Previous page
‹ previous
Page
1
Page
2
Current page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy